PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Ra...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Medicine (Baltimore)
Main Authors: Wang, Man Cai, Zhang, Ling Yi, Han, Wei, Shao, Yuan, Chen, Mo, Ni, Rui, Wang, Gen Nian, Wei, Feng Xian, Zhang, Ya Wu, Xu, Xiao Dong, Zhang, You Cheng
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2014
Teme:
4200
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603082/
https://ncbi.nlm.nih.gov/pubmed/25526490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000000326
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki